Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 7 June 2007 - 9 January 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study has been performed according to OECD guidelines and according to GLP principles.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: "28-day Repeated Dose Toxicity Study in Mammalian Species" prescribed in "Concerning Testing Methods Relating to the New Chemical Substances" (Notification No. 1121002, MHLW, No. 2 (November 13, 2003), METI & No. 031121002, MOE (November 21, 2003))
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): S-500
- Substance type: yellow powder
- Physical state: solid
- Lot/batch No.: MF1456-2345
- Stability under test conditions: stable (confirmed by IR)
- Storage condition of test material: at room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan Inc. (Hino Breeding Center; 735, Shimokomatsuki, Hino-cho, Gamo-gun, Shiga 529-1633, Japan)
- Age at study initiation: 5 weeks old
- Weight at study initiation: 136.1-169.2 g (males) and 118.1-144.3 (females)
- Fasting period before study: not applicable
- Housing: stainless steel hanger cages with wire-mesh floor.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 10 days, including 6 days quarantine
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.1-23.9
- Humidity (%): 48.5-62.0
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: CMC-Na (carboxymethyl cellulose sodium salt)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was suspended with 0.5 w/v% CMC-Na solution in a mortar to 10.0 w/v% formulation (i.e. 100 mg/mL). The lower concentrations of 2.5 and 0.5 w/v% suspensions were diluted from 10.0 w/v% suspension. These were prepared once per 7 or 8 days and stored at the dark and cold place.
VEHICLE
- Justification for use and choice of vehicle (if other than water): when the preparation method of the dosing formulation method was investigated, the test substance was not dissolved in purified water but suspended with 0.5 w/v% CMC-Na solution (in purified water).
- Concentration in vehicle: 0.5% (w/v%) CMC-Na solution in purified water is used to prepare dose formulations: 0.5, 2.5 and 10 w/v% test substance, i.e. 5, 25 and 100 mg/ml.
- Amount of vehicle (if gavage): 10 mL/kg
- Lot/batch no. (if required): purified water: 070326A, CMC-Na: LT - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- At the start (first preparation) and the last (last preparation) of dosing, middle layers of 10.0, 2.5 and 0.5 w/v% formulations were taken (n=1) just after preparation, and quantitatively analyzed once for each by HPLC (n=1) after sample pretreatment.
The test substance in 10.0 and 0.5 w/v% formulations was stable for 8 days after preparation at cold and dark place and showed good homogeneity.
The concentration of test substance in 10.0, 2.5 and 0.5 w/v% dose formulations for subject study at the first and final preparation was acceptable level (ratio actual/nominal concentration: 99.6-102%). - Duration of treatment / exposure:
- 28 days exposure, followed by 14 days recovery period.
- Frequency of treatment:
- daily in the morning.
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
50 mg/kg bw/d
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
250 mg/kg bw/d
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw/d
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: A 14-day repeated oral dose toxicity study was performed at 4 doses: 25, 250, 500 and 1000 mg/kg bw/d. As a result, no adverse effects attributable to the test substance were noted in males and females of all dose groups.
- Rationale for animal assignment (if not random): ensuring homogeneity of mean body weights using body weight-stratified randomization
- Rationale for selecting satellite groups: not indicated
- Post-exposure recovery period in satellite groups: control and 1000 mg/kg bw/d dose groups for 14 days.
- Section schedule rationale (if not random): not indicated - Positive control:
- not applicable
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily during dosing period: before, during and after dosing and in the afternoon. Daily during the recovery period: in the morning and in the afternoon.
- Cage side observations: general condition: mortality, stool, fur, scab formation
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once before dosing in all animals. Thereafter, on a blind test basis once weekly during the dosing and recovery periods.
BODY WEIGHT: Yes
- Time schedule for examinations: on day before dosing, and on days 1, 3, 8, 12, 17, 21, 26 and 28 during dosing period, and on days 1, 5, 10 and 14 during recovery period. And immediately before necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No, as g food/rat/day.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: end of dosing period or recovery period
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes, overnight for 16-20 h
- How many animals: all
- Parameters examined: red blood cell count, white blood cell count, hemoglobin conc., hematocrit value, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, prothrombin time, activated partial thromboplastin time, differentiation of leucocytes (neutrophils, eosinophils, basophils, lymphocytes, monocytes, large unstained cells)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: end of dosing period or recovery period
- Animals fasted: Yes, overnight for 16-20 h
- How many animals: all
- Parameters examined: asparate aminotransferase, alanine aminotransferase, alkaline phosphatase, cholinesterase, gamma-glutamyl transpeptidase, total cholesterol, triglyceride, glucose, total protein, albumin, A/G ratio, blood urea nitrogen, creatinine, total bilirubin, calcium, inorganic phosphorus, sodium, potassium, chloride
URINALYSIS: Yes
- Time schedule for collection of urine: end of dosing period or recovery period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes, but drinking water ad libitum
- Parameters examined: urine volume, colour, turbidity, urine specific gravity, pH, protein, glucose, occult blood, urinary sediments.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: week 4 of dosing
- Dose groups that were examined: all animals
- Battery of functions tested: reflex test / locomotor activity / grip strength - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Body surface, all orifices, subcutaneous tissue, cranial, thoracic, abdominal and pelvic cavities, and contents.
ORGAN WEIGHTS: Yes
Liver, kidneys, heart, testes, epididymides, ovaries, brain , spleen, thymus and adrenals.
HISTOPATHOLOGY: Yes
Trachea, lungs, forestomach, glandular stomach, duodenum, jejunum, ileum, cecum, colon, rectum, liver, heart, kidneys, urinary bladder, testes, pididymides, prostate, seminal vesicles, ovaries, uterus, vagina, cerebrum, cerebellum, pons, spinal cord, sciatic nerve, bone marrow, axillar and mesenteric lymph nodes, spleen, thymus, pituitary gland, thyroids, parathyroids, adrenals, eye balls. - Other examinations:
- Not applicable.
- Statistics:
- Bartlett's test for homogeneity of variance.
Dunnett's test for the difference between vehicle and exposed group (if variances were homogenous at 5% significance level)
Nonparametric Dunnett's test for the difference between vehicle and exposed group (if variances were not homogenous)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Yellow stool was continuously observed in both sexes of 250 and 1000 mg/kg groups. Yellow stool was not observed two days after termination of dosing in both sexes of 1000 mg/kg recovery group.
HAEMATOLOGY
Hemoglobin concentration was decreased statistically in males of 1000 mg/kg group and ratio of large unstained cells was increased statistically in females of the 1000 mg/kg group at termination of the dosing period. These changes (after dosing period) were however within the historical control data.
CLINICAL CHEMISTRY
Sodium was increased statistically in males of the 1000 mg/kg group after dosing period. This change was however within the historical control data.
ORGAN WEIGHTS
Increases in relative liver and spleen weights in males of the 1000 mg/kg group after recovery period were noted. There were however no histopathological changes and these changes were within the historical control data.
GROSS PATHOLOGY
Incidental changes occurred, in small numbers, and often in normal animals.
After dosing period: cyst pituitary gland (1 male, 1000 mg/kg), diverticulum of jejunum (1 female, 1000 mg/kg), smaller left lobe of thyroid (1 female, 250 mg/kg), small testis (1 male, control).
After recovery period: recessed region of kidney (1 female, 1000 mg/kg), pelvic dilatation of kidney (1 male, control), diverticulum of jejunum (1 female, control)
HISTOPATHOLOGY: NON-NEOPLASTIC
Incidental changes occurred, in small numbers, and often in normal animals.
After dosing period:
- cyst formation in pars nervosa of pituitary gland (1 male, 1000 mg/kg) (same animal as mentioned under GROSS PATHOLOGY)
- diverticulum jejunum (1 female, 1000 mg/kg) (same animal as mentioned under GROSS PATHOLOGY)
- hypolasia of left lobe in thyroid (1 female, 250 mg/kg) (same animal as mentioned under GROSS PATHOLOGY)
- subcapsular solitary cyst in medulla of kidney (1 male, 1000 mg/kg)
- solitary cyst in medulla of kidney (1 male, 1000 mg/kg)
- increased follicular cysts of ovary and mineralization in cortico-medullary junction of kidney (1 female, 1000 mg/kg)
- mineralization in cortico-medullary junction of kidney (1 female, 1000 mg/kg and 1 female, control)
- degeneration of spermatocytes or inhibited spermiation and deep retention of spermatids of the testis and decreased spermatozoa in lumen or germ cell debris in lumen of the epididymis (1 male, control) (same animal as mentioned under GROSS PATHOLOGY)
- karyomegaly of tubular epithelium in corticomedullary junction of kidney (1 male, control)
- ectopic ossification of adrenal (1 male, control)
- ultimobranchial rest of thyroid (1 female, control)
- ectopic striated muscle of lung (1 female, control)
After recovery period:
- focal atrophy of nephrons with lymphocyte infiltration and fibrosis in kidney (1 female, 1000 mg/kg) (same animal as mentioned under GROSS PATHOLOGY)
- microgranuloma of liver (1 male, 1000 mg/kg)
- pelvic dilation in kidney (1 male, control) (same animal as mentioned under GROSS PATHOLOGY)
- focal diverticulum in jejunum (1 female, control) (same animal as mentioned under GROSS PATHOLOGY)
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: No abnormalities caused by the test substance were noted in the test. Yellow stool (at 250 and 1000 mg/kg bw dose groups) were an effect from the yellow colour of the test substance.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- S-500 was orally administered by gavage to Crl:CD(SD) rats at doses of 50, 250 and 1000 mg/kg bw/day to perform a 28-day toxicity study followed by a 14-day recovery study.
Yellow stool was noted in males and females of the groups of 250 mg/kg and more. This change was not considered to be of toxicological significance since the effect is due to the colour of the test substance.
No abnormalities attributable to the test substance were observed in detailed clinical observations, sensorimotor functions, body weights, food intakes, hematological examinations, blood chemical examinations, urinalyses or pathological examinations. No abnormalities were also noted in the recovery test.
From the above mentioned results, the NOEL of S-500 in rats under the present study conditions was estimated to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies